WEST PHARMACEUTICAL SERVICES INC
For the period ended Mar 31, 2025. Filed Apr 24, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed Apr 24, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
The following table shows information with respect to purchases of our common stock made during the three months ended March 31, 2025 by us or any of our “affiliated purchasers” as defined in Rule 10b-18(a)(3) under the Exchange Act:
| Period | Total number of shares purchased (1) | Average price paid per share (1) | Total number of shares purchased as part of publicly announced plans or programs (1) | Maximum number of shares that may yet be purchased under the plans or programs (1) |
|---|---|---|---|---|
| January 1 - 31, 2025 | 46,069 | $336.96 | 46,069 | 506,524 |
| February 1 - 28, 2025 | 43,586 | $269.18 | 43,586 | 462,938 |
| March 1 - 31, 2025 | 460,626 | $230.68 | 460,626 | 2,312 |
| Total | 550,281 | $242.63 | 550,281 | 2,312 |
(1)In February 2023, the Board of Directors approved a share repurchase program under which we may repurchase up to $1.0 billion in shares of common stock. 2,593 shares purchased during the period were under the February 2023 plan, which completed the plan during January 2025. Additionally, during December 2024, the Board of Directors approved a share repurchase program under which the Company may repurchase up to 550,000 shares of common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions depended on a variety of factors, including market conditions. 547,688 shares purchased during the three months ended March 31, 2025 were under the December 2024 plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.